In addition to inhibiting tumor growth, the MF59 and CpG compound adjuvant also triggered a Th1 immune response through the mucin 1 (MUC1)-maltose-binding protein (MBP) (MM) vaccine, leading to increased survival time in both preventive and therapeutic mice (54). Here, MBP is linked to neoplasm.